Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.76 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.76 |
| ▸ | ARHGDIA | P52565 | 5/20 | 0.76 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412871 | 0.84 | ROCK2 (0.53) | ROCK2ROCK1ARHGDIAJAK1KCNH2 | |
| SCHEMBL1974051 | 0.77 | ROCK2 (1.00) | ROCK2ROCK1ARHGDIACCR2 | |
| SCHEMBL5415101 | 0.75 | ROCK1 (0.41) | ROCK2ROCK1ARHGDIAJAK1 | |
| SCHEMBL5412926 | 0.73 | ROCK2 (0.46) | ROCK2ROCK1ARHGDIAJAK1LTA4H | |
| SCHEMBL1974858 | 0.71 | ROCK2 (1.00) | ROCK2ROCK1ARHGDIACCR2 | |
| SCHEMBL3527134 | 0.70 | ROCK2 (0.59) | ROCK2ROCK1ARHGDIALTA4HOPRK1 | |
| SCHEMBL4019763 | 0.69 | ROCK2 (0.55) | ROCK2ROCK1ARHGDIAJAK1LTA4H | |
| SCHEMBL4019760 | 0.69 | ROCK2 (0.55) | ROCK2ROCK1ARHGDIAJAK1LTA4H | |
| SCHEMBL5413391 | 0.69 | ROCK2 (0.72) | ROCK2ROCK1ARHGDIAOPRK1MEN1 | |
| SCHEMBL6536312 | 0.69 | ALDH1A1 (0.58) | ROCK2ROCK1ARHGDIALTA4HOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885ARHGDIA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.